It suggested that there was, in general, insufficient evidence that the effect of treatment depended on baseline characteristics [12], even though some preliminary studies suggest that, in RA patients having an inadequate response to MTX, those having a disease of limited duration associated with high levels of anti-CCP antibodies and/or with presence of shared epitope, had higher efficacy responses versus ADA after 24 weeks [13, 14]. Here, ADA is linked to rheumatoid arthritis.